RBR-6p8c6dActive, not recruiting未知
Measuring the Autistic Spectrum Disorder (ASD)
niversidade Federal de Uberlândia0 sitesStarted: December 6, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18Y to 82Y (—)
Inclusion Criteria
- •Adults higher 18 years, who have agreed to participate in the study and belonging to one of the following categories: Group1 formed by individuals diagnosed with atipical autism; Group2 individuals of the general population of Uberlândia; Group3 academic of the Universidade Federal de Uberlândia, and Grup4 formed by clevers adults, i.e, individuals approved in first place in a public service.
Exclusion Criteria
- •Individuals with less than 18 years and individuals who were unable to complete the questionnaire for any reason, such as dementia, aphasia or illiteracy were excluded.
Investigators
Similar Trials
Active, not recruiting
Phase 1
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
Active, not recruiting
Phase 1
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboOpioid-induced constipation in subjects with advanced illnessMedDRA version: 13.1Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
Active, not recruiting
Not Applicable
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201MedDRA version: 8.1Level: PTClassification code 10011078Coronary Artery DiseaseEUCTR2005-006029-94-BEEisai Limited720
Completed
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82